AGP Executive Report
Last update: 8 hours agoChina Pharma Deals: JW Therapeutics’ CEO says tighter Beijing scrutiny over sensitive tech deals hasn’t slowed its cross-border collaborations, especially in cell and gene therapies. Rare Disease Access: Sanofi launches AccelRare in India, an AI pre-diagnosis tool aimed at cutting rare-disease diagnostic delays. Biosimilars Policy Gaps: A new study highlights uneven global biosimilar rules that slow development and limit patient access. FDA/Antibiotics Milestone: Wockhardt’s Zaynich (cefepime + zidebactam) wins USFDA approval for complicated UTIs, underscoring the push against antimicrobial resistance. Healthcare Operations: Penn researchers warn extreme heat worsens underlying conditions and argue for expanded cooling assistance tied to energy insecurity. Clinical Highlights (Oncology): ASCO updates include durable survival benefits with pembrolizumab in early TNBC (KEYNOTE-522) and a major pancreatic cancer advance with daraxonrasib nearly doubling median survival vs chemotherapy. Care Delivery Tech: Medical practices are adopting AI receptionists to ease staffing strain and reduce missed calls/no-shows.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
